| |
Reyataz Reduced CVD Risk
|
| |
| |
Reyataz Reduced CVD Risk Compared with other ART Regimens - Cardiovascular outcomes among HIV-infected veterans receiving atazanavir: a US national historical cohort study - (07/21/17)
Participants: Treatment-naive patients with HIV infection (N = 9500).
"In this population of primarily older males, ATV-containing regimens were associated with an adjusted 54% reduced risk of MI and 36% reduced risk of stroke compared with non-ATV-containing regimens. This significant reduction in MI and stroke risk in the primary analysis was consistently observed across all comparisons between regimens containing ATV and other PIs, NNRTIs, or INSTIs."
Incidence rates for MI, stroke, and all-cause mortality with atazanavir-containing regimens (5.2, 10.4, and 16.0 per 1000 patient-years, respectively) were lower than with regimens containing other PIs (10.2, 21.9, and 23.3 per 1000 patient-years), NNRTIs (7.5, 15.9, and 17.5 per 1000 patient-years), or INSTIs (13.0, 33.1, and 21.5 per 1000 patient-years). After IPTW, adjusted hazard ratios (95% confidence intervals) for MI, stroke, and all-cause mortality with atazanavir-containing regimens versus all non-atazanavir-containing regimens were 0.59 (0.41-0.84), 0.64 (0.50-0.81), and 0.90 (0.73-1.11), respectively.
One Third Lower MI Risk With Atazanavir Than Other ARVs in US
At Glasgow 2016
Risk of Cardiovascular Disease Events With Atazanavir-Based Antiretroviral Treatment Regimens
Among HIV-Infected Veterans: A US National Study
J LaFleur,1,2A Bress,2,3L Rosenblatt,4J Crook,2,5PE Sax,6J Myers,4C Ritchings4
1Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA;
2Salt Lake City VA Health Care System, Salt Lake City, UT, USA;
3Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA;
4Bristol-Myers Squibb Company, Princeton, NJ, USA;
5Division of Epidemiology, University of Utah, Salt Lake City, UT, USA;
6 Brigham and Women’s Hospital and Harvard Medical School,
|
|
| |
| |
|
|
|
